Clinical Transplantation最新文献

{"title":"Which Donor and Recipient Risk Factors Matter in Heart Transplantation? Results From a Survey of 53 Centers Across Five Countries","authors":"Sabina P. W. Guenther,&nbsp;René Schramm,&nbsp;Jeffrey J. Teuteberg,&nbsp;Yasuhiro Shudo,&nbsp;Anna L. Rogge,&nbsp;Katharina E. Schaeper,&nbsp;Henrik Fox,&nbsp;Lisa Hoepner,&nbsp;Chawannuch Ruaengsri,&nbsp;Angelika Costard-Jaeckle,&nbsp;William Hiesinger,&nbsp;Y. Joseph Woo,&nbsp;Michiel Morshuis,&nbsp;Kiran K. Khush,&nbsp;Jan F. Gummert,&nbsp;Brian J. Wayda","doi":"10.1111/ctr.70214","DOIUrl":"https://doi.org/10.1111/ctr.70214","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Consensus regarding what defines acceptable heart transplant (HT) donors or recipients is lacking. This survey analyzed how risk factors guide donor and recipient selection, and how practices vary across systems.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>An online survey was conducted among adult HT centers in the US and Eurotransplant (ET) region. We aimed to represent at least 50% of the total adult HT volumes in both regions. Centers were stratified by their HT volumes. To compensate for non-responders, a safety margin was included, and centers accounting for at least 75% of the total HT volumes were contacted. Centers were queried on relative thresholds and absolute cutoffs for continuous risk factors. For other factors, their influence on donor heart acceptance or the likelihood of listing recipients was assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Fifty-three centers from five countries participated: 39 US (accounting for 51.0% of the US HT volume), and 14 ET centers (65.0%) from four countries. ET centers more liberally considered advanced age donor hearts (threshold 64.5 [60.0–70.0] vs. 50.0 [50.0–55.0] years, <i>p</i> &lt; 0.001), and hearts with abnormal echocardiography or coronary findings. Diabetes, smoking, and hypertension were rated by a quarter to more than half of US and ET centers as moderately or heavily influencing donor heart acceptance. ET centers more liberally listed candidates with chronic kidney disease (GFR 30.0 [21.5–32.5] vs. 35.0 [30.0–40.0] mL/min/1.73m², <i>p</i> &lt; 0.001). US centers, conversely, allowed for higher candidate ages (71.5 [70.0–74.0] vs. 68.0 [65.0–70.0] years, <i>p</i> &lt; 0.001), and more likely (76.9%) listed candidates on ECMO support (42.9% of ET centers to less likely list, <i>p</i> = 0.022).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Selection practices differed distinctly between the US and ET. Further, practices appear to be driven by caution and are more conservative than current guidelines. Strengthening the evidence base to objectify and optimize donor and candidate selection could help alleviate the unmet need for donor hearts.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144315092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationships Between Nutrition Risk and Frailty in Candidates for Lung Transplant","authors":"Brooke Stewart,&nbsp;Rebecca Brody,&nbsp;Hamed Samavat,&nbsp;Laura Byham-Gray,&nbsp;Noori Chowdhury,&nbsp;Sunita Mathur,&nbsp;Lianne G. Singer","doi":"10.1111/ctr.70205","DOIUrl":"https://doi.org/10.1111/ctr.70205","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Healthcare teams evaluating candidates for lung transplant seek to identify and address modifiable factors to improve their clinical outcomes. Frailty may be a modifiable factor, and poor nutrition may be a contributor to frailty. This study evaluated the relationship between nutrition risk and frailty in lung transplant candidates.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a secondary analysis of data from 62 adult lung transplant candidates. Nutrition risk was assessed with the Seniors in the Community: Risk Evaluation for Eating and Nutrition (SCREEN-14) questionnaire, and frailty was measured using two methods: physical frailty with the Fried frailty index (FFI) and multidimensional frailty using a cumulative deficits frailty index (CDFI), where higher scores on a 0–1 scale denote increasing frailty. Pearson correlation, independent-samples <i>t</i>-test, and Fisher's exact tests analyzed associations between SCREEN-14 and both FFI and CDFI scores.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Most participants were at high nutrition risk (83.9%) and were pre-frail (69.4%) or frail (17.7%) when assessed using FFI. Mean CDFI score was 0.26. Higher nutrition risk was associated with a higher degree of frailty as measured using FFI (<i>r</i> = −0.303; <i>p</i> = 0.017) but not CDFI. Participants at high nutrition risk were significantly more likely to be pre-frail or frail by FFI than those at low nutrition risk (92.3% vs. 60.0%, respectively; <i>p</i> = 0.019).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>High nutrition risk is highly prevalent and associated with physical frailty in lung transplant candidates. Future studies should investigate how to best identify nutrition risk and whether interventions that reduce this risk also decrease frailty.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ctr.70205","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144308904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “A Tailored Virtual Program for Alcohol Use Disorder Treatment Among Liver Transplant Candidates and Recipients is Feasible and Associated With Lower Post-Transplant Relapse”","authors":"","doi":"10.1111/ctr.70216","DOIUrl":"https://doi.org/10.1111/ctr.70216","url":null,"abstract":"<p>A. Goswami, E. Weinberg, L. Coraluzzi, et al., “A Tailored Virtual Program for Alcohol Use Disorder Treatment Among Liver Transplant Candidates and Recipients is Feasible and Associated With Lower Post-Transplant Relapse,” <i>Clinical Transplantation</i> 38, no. 7 (2024): e15381, https://doi.org/10.1111/ctr.15381</p><p>In the article cited above, the authorship has changed to include Dr. Angela Burdick-Mcphee as the fifth author.</p><p>Dr. Mcphee provided excellent work in conducting both partitioning patients included in this study and in working to gather data that served as key components of the primary findings of the paper.  Her contributions to this work have subsequently been reviewed by the authors and fully meet the criteria for authorship as defined by the University of Pennsylvania School of Medicine. Dr. Burdick-Mcphee has read and approved the manuscript, and all other authors agree to this request.</p><p>The correct authorship for this article is listed below:</p><p>Arpita Goswami, Ethan Weinberg, Lynda Coraluzzi, Therese Bittermann, <b>Angela Burdick-Mcphee,</b> Jonathan Nahas, Senayish Addis, Robert Weinrieb, Marina Serper</p><p>We apologize this error.</p>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ctr.70216","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144281609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Calcineurin Inhibitor Replacement With Mammalian Target of Rapamycin (mTOR) Inhibitor Following Lung Transplantation","authors":"Kavya Kommaraju,&nbsp;Muath Alsharif,&nbsp;John P. Scott,&nbsp;Kelly M. Pennington","doi":"10.1111/ctr.70211","DOIUrl":"https://doi.org/10.1111/ctr.70211","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Calcineurin inhibitors (CNIs) are the cornerstone of lung transplant immunosuppression but are associated with nephrotoxicity and other adverse effects. Although dose reduction and combination with Sirolimus, a mammalian target of rapamycin inhibitor (mTORi), have been explored, full conversion to Sirolimus remains uncommon. This study describes the characteristics and outcomes of lung transplant recipients who underwent complete CNI withdrawal and conversion to Sirolimus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective case series included 52 lung transplant recipients transitioned to Sirolimus-based immunosuppression between 2010 and 2021. Data on demographics, transplant characteristics, immunosuppression, and outcomes were collected from electronic medical records.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The cohort included 31 males (59.6%) with a median age of 58.4 years (IQR 52.3–63.5). The primary indication for CNI withdrawal was renal dysfunction (73.1%). Sirolimus discontinuation occurred in 69.2%, most commonly due to edema (25.0%), lung toxicity (19.4%), rejection (19.4%), and surgical needs (22.2%). Clinically significant rejection occurred in 13.5%, with four patients progressing to chronic lung allograft dysfunction (CLAD) and two deaths. Sixteen patients (30.8%) tolerated CNI withdrawal for over a year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Full conversion from CNI to Sirolimus is poorly tolerated due to side effects and has a high incidence of rejection. Further studies are needed to optimize patient selection and risk mitigation strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144281614","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Outcomes of Hematopoietic Stem Cell Transplantation in Mucopolysaccharidoses Patients Without Radiation","authors":"Mohammad Jahanpanah,&nbsp;Leila Jafari,&nbsp;Maryam Behfar,&nbsp;Nadia Alipour,&nbsp;Farah Ahad,&nbsp;Rashin Mohseni,&nbsp;Reihaneh Mohsenipour,&nbsp;Aria Setoodeh,&nbsp;Morteza Heidari,&nbsp;Mahmoud Reza Ashrafi,&nbsp;Reza Shervin Badv,&nbsp;Mina Mokaram,&nbsp;Shirin Eshghi,&nbsp;Amir Ali Hamidieh","doi":"10.1111/ctr.70188","DOIUrl":"https://doi.org/10.1111/ctr.70188","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 <p>Mucopolysaccharidosis (MPS) is an inherited lysosomal storage disorder (LSD) subcategory caused by the glycosaminoglycans (GAG) endo- and exo-glycosidases malfunction or dysfunction, leading to GAG accumulation. Due to the enzyme replacement therapy's (ERT's) limitations and challenges, HSCT is considered the only standard curative option in some MPS subtypes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The cross-sectional study was conducted on MPS subtypes I, II, and VI patients with an indication for HSCT between September 2016 and December 2023. A myeloablative conditioning (MAC) regimen without radiation was administered to all patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In this study, the OS was 75.3% for all patients. Considering different MPS subtypes, the OS rate was 71.6%, 62.5%, and 81.3% for MPS-I, II, and VI patients, respectively. There was no graft failure using PB donor cells, and all alive patients reached normal enzyme activity 1 year post-HSCT. Considering growth parameters, we showed that MPS I patients could benefit from HSCT more than MPS VI patients. However, MPS VI patients showed better OS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Data regarding the comparison of HSCT outcomes in different MPS subtypes are limited, and HSCT outcomes in MPS VI patients are mostly limited to case reports. A conditioning regimen without radiation should be considered in all patients to reduce post-HSCT complications.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144273126","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Targeted Posaconazole Prophylaxis in Heart Transplant Recipients During an Outbreak of Early Invasive Aspergillosis","authors":"Malo Penven,&nbsp;Céline Goeminne,&nbsp;Camille Ternynck,&nbsp;Severine Loridant,&nbsp;Agnès Perrin,&nbsp;Benjamin Valentin,&nbsp;Karine Faure,&nbsp;Sarah Stabler,&nbsp;Emmanuel Faure,&nbsp;Fanny Vuotto","doi":"10.1111/ctr.70210","DOIUrl":"https://doi.org/10.1111/ctr.70210","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>There are no established recommendations for systematic or targeted antifungal prophylaxis in heart transplant recipients (HTRs), resulting in heterogeneous practices. An outbreak of post-surgical invasive aspergillosis (IA) among HTR, which coincided with construction activities near our heart transplant unit, prompted the initiation of primary posaconazole (POS) prophylaxis in patients at highest risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This single-center retrospective descriptive study was conducted from March 2020 to May 2022 and describes the use of POS primary prophylaxis in high-risk HTR. The following risk factors were considered as indications for initiating prophylaxis: re-operation, post-transplantation hemodialysis, post-surgical extracorporeal membrane oxygenation (ECMO), re-transplantation, prolonged post-transplant mechanical ventilation (i.e., &gt;72 h), cytomegalovirus (CMV) infection within the first month post-transplant, and a positive pre-transplant <i>Aspergillus</i> serology. The duration of prophylaxis was individualized, with treatment initiating in response to the risk factor and continuing for a median of 28 days after its resolution.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>POS prophylaxis was administered in 12 of 33 HTR (36.4%). The most common risk factors encountered were prolonged mechanical ventilation (&gt;72 h, 91.6%) and CMV infection (58.3%). Most patients (91.6%) had at least two risk factors for IA, and more than half (58.3%) had three or more. Notably, no cases of IA were observed during the study period. Some patients experienced liver function abnormalities and drug–drug interactions.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Targeted POS prophylaxis may be an option for high-risk HTR during an outbreak. Close monitoring of liver function, POS levels, and tacrolimus concentrations is recommended.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ctr.70210","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144273127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tacrolimus Intrapatient Variability as a Biomarker in Solid Organ Transplantation","authors":"Rita Nogueiras-Álvarez,&nbsp;María del Mar García-Saiz","doi":"10.1111/ctr.70197","DOIUrl":"https://doi.org/10.1111/ctr.70197","url":null,"abstract":"<div>\u0000 \u0000 <p>Tacrolimus is the primary calcineurin inhibitor agent prescribed in different solid organ transplantation modalities. Among its characteristics, tacrolimus has a high inter- and intrapatient variability. Recently, tacrolimus intrapatient variability (Tac-IPV) has been proposed as a useful biomarker to predict outcomes in different types of solid organ transplantation. This work includes a systematic review of the literature that evaluates Tac-IPV influence on solid organ transplantation outcomes from inception to September 18, 2024. Although there are several publications assessing the influence of Tac-IPV in transplantation, we found that there is a lack of consensus regarding which is the best measure to evaluate Tac-IPV. Moreover, the ideal post-transplantation period for evaluating this biomarker has not been established so far. Different cut-off points have been proposed, especially in adult kidney transplantation, where most of the studies have been carried out, but these cut-off values may not be applicable to other transplantation modalities. This work includes a description of the main findings of different studies in an attempt to state what the current knowledge on the topic is in different solid organ transplantation modalities.</p>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144264676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Cardiovascular Biomarkers With Cardiac Allograft Vasculopathy and Atherosclerotic Coronary Artery Disease","authors":"Lukas Köster,&nbsp;Jessica Weimann,&nbsp;Alexander Bernhard,&nbsp;Benjamin Bay,&nbsp;Christopher M. Blaum,&nbsp;Thiess Lorenz,&nbsp;Tanja Zeller,&nbsp;Christoph Waldeyer,&nbsp;Hermann Reichenspurner,&nbsp;Paulus Kirchhof,&nbsp;Stefan Blankenberg,&nbsp;Christina Magnussen,&nbsp;Fabian J. Brunner","doi":"10.1111/ctr.70195","DOIUrl":"https://doi.org/10.1111/ctr.70195","url":null,"abstract":"<p>Background: Cardiac allograft vasculopathy (CAV) remains a barrier to long-term survival after heart transplantation. Little is known about cardiovascular biomarkers in CAV and how they compare to biomarkers in atherosclerotic coronary artery disease (CAD).</p><p>Purpose: This study addresses these gaps by investigating the associations of high-sensitivity troponin I and T (hsTnI/T), N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity C-reactive protein (hsCRP) with CAV and CAD.</p><p>Methods: Posttransplant patients undergoing angiography were matched 1:2 with nontransplant patients by age, sex, hypertension, BMI and angiographic severity of CAV and CAD. Disease severity was classified using the International Society for Heart and Lung Transplantation.</p><p>Results: Sixty-three transplant and 126 matched nontransplant patients (median age 55.9 years, 5.8 years posttransplant, 8.5% female) were analyzed. Among transplant patients, 17.5% had mild, 7.9% moderate, 7.9% severe, and 66.7% no CAV. HsTnI/T (OR per SD = 2.21/2.38, CI = 1.17–4.66/1.21–5.69, <i>p</i> = 0.022/0.026) and NT-proBNP (OR per SD = 2.86, 95% CI 1.50–6.39, <i>p</i> = 0.004) were significantly associated with CAV. While hsTnT (OR per SD = 1.60, 95% CI 1.06–2.52, <i>p</i> = 0.030) and hsCRP (OR per SD = 1.61, 95% CI 1.08–2.47, <i>p</i> = 0.023) were significantly associated with CAD.</p><p>Conclusion: Distinct biomarker profiles were observed: HsTnI, hsTnT, and NT-proBNP showed associations with CAV, while hsTnT and hsCRP were associated with CAD.</p>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ctr.70195","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144244691","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduction in Belatacept Dosing Frequency to Every 2 Months for Kidney Transplant Patients at High Risk of Infections","authors":"Johanna Christensen,&nbsp;Randi Thompson,&nbsp;Amber Paulus,&nbsp;Carly Amato-Menker,&nbsp;Dhiren Kumar,&nbsp;Inkoo Lee,&nbsp;Gaurav Gupta","doi":"10.1111/ctr.70212","DOIUrl":"https://doi.org/10.1111/ctr.70212","url":null,"abstract":"","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144244651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatitis C Nucleic Acid Test Positive (NAT+) Solid Organ Consent Rates Are Highest in Patients Listed for Liver Transplant and With an English Language Preference","authors":"Sachiko M. Oshima,&nbsp;Alice Parish,&nbsp;Jacqueline B. Henson,&nbsp;Mariya Samoylova,&nbsp;Donna Niedzwiecki,&nbsp;Lisa McElroy,&nbsp;Lindsay King,&nbsp;Julius M. Wilder,&nbsp;Kara Wegermann","doi":"10.1111/ctr.70186","DOIUrl":"https://doi.org/10.1111/ctr.70186","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Transplantation of hepatitis C virus (HCV) nucleic acid (NAT) positive organs is associated with shorter time to transplant and decreased risk of death on the waiting list. Treatment for HCV post-transplant is well-tolerated, successful, and leads to similar transplant outcomes to patients transplanted with HCV NAT− organs. Despite these outcomes, not all patients consent to receive HCV NAT+ organs, and factors associated with consent are not well-known.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective single-center study of adult patients listed for heart, liver, lung, and kidney transplant aimed to determine whether sociodemographic and organ-specific disparities exist in consent for HCV NAT+ donor organs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Of 2788 transplant candidates, 44% (<i>N</i> = 1229) consented to receive an HCV NAT+ organ. Patients who designated English as their preferred language were more likely to consent compared to a non-English preference (45% vs. 19%, <i>p</i> &lt; 0.001). Consent rates were highest amongst patients listed for liver transplantation compared to kidney, heart, and lung transplants (67%, <i>N</i> = 319 vs. 42%, <i>N</i> = 602 vs. 38%, <i>N</i> = 159 vs. 32%, <i>N</i> = 149; <i>p</i> &lt; 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Overall, more efforts are needed to ensure that all patients who may benefit from consenting for HCV NAT+ organs are appropriately educated in their language of choice on the risks and benefits.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10467,"journal":{"name":"Clinical Transplantation","volume":"39 6","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144244662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}